PE-22-28

Read 1. No self-reporter in this sample could be verified as a man aged 45–60, and none unambiguously established male sex. Among 10 coded users, reported experiences ranged from substantial mood improvement to no effect or worsened mood and energy. One user reported improvement after almost two months, whereas another initially described fewer crying episodes but later concluded that six weeks of use had made no difference. Negative reports included emotional flatness, low energy, and nausea, sometimes during simultaneous use of other compounds. The evidence is especially thin because several relevant threads contain questions rather than completed self-experiments.

Read 2. No man aged 45–60; one identifiable man. Most threads were people asking whether it helps depression. All three actual self-reporters were negative: two felt physically slower, lethargic and emotionally flat (one also noted cycle disruption), and one who stacked it with Selank and Semax had severe nausea three hours after injecting. Reliability very low.

Note 1. Sparse, self-selected evidence. An initial favorable report was replaced by the same author's later no-effect verdict. A combined Selank/Semax/PE-22-28 nausea report is counted as stacked and does not establish which compound caused nausea. An ambiguous reference to PT-22-28 and future-use plans were excluded. No reliable typical dose or duration could be calculated.

Note 2. 6 of 8 threads were prospective questions or avoidance discussions. Two self-reports were only available in Norwegian and Arabic translations.

Each read counted people independently. Overlap between the two reads is estimated from shared threads and removed; counts are approximate. How we count.